Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ENSG00000259993 target encodes a pseudogene related to hyperpolarization-activated cyclic nucleotide-gated potassium channel 2 (HCN2). Pseudogenes are non-coding genomic sequences derived from ancestral genes and are generally considered non-functional in terms of protein-coding activity. In contrast, the functional HCN2 channel is an ion channel modulating neuronal and cardiac excitability, but this activity does not apply to the pseudogene. As such, ENSG00000259993 is not recognized as a drug target, has no associated therapeutic drugs or biomarkers, and holds no established disease relevance. Key caveat: Much of the literature and drug/biomarker knowledge pertains to HCN2 protein and its encoding gene, not the pseudogene ENSG00000259993. If your goal is to retrieve data on a therapeutic target, you should refer to the HCN2 gene itself (canonical name: Hyperpolarization-activated cyclic nucleotide-gated potassium channel 2, abbreviation: HCN2), an established ion channel involved in various pathologies. For the actual pseudogene ENSG00000259993, none of the typical drug target fields apply.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hyperpolarization-activated cyclic nucleotide-gated potassium channel 2 pseudogene.